Category

News

Competitive, fast, and adaptable RNA Sequencing services

By | News | No Comments

RNA sequencing is an affordable and dependable tool driving R&D and clinical projects. To answer scientific challenges, GenomeScan develops innovative methods to analyze RNA samples. Minute populations of sorted cells or FFPE samples are no longer hampering progression of your project. Get direct access to a wide range of RNA-seq services under ISO/IEC 17015 accreditation. Our experienced scientific team can determine with you the optimal solution to reach your objectives. Tell us more about your project to get started.

Recently, we co-authored a study involving RNASeq published in a high-impact journal. Read the full article in Cell.

You can review our RNASeq service portfolio on the website.

07.04.2019 RNAseq for all sample types 1 Competitive, fast, and adaptable RNA Sequencing services

How to generate high-quality, alignable sequence data?

By | News | No Comments

Innovation Alert: Mid-read sequencing

Sequencing of PE250 reads on the NovaSeq 6000

 

PE250 reads fig.1 How to generate high quality, alignable sequence data?

Printing a book of more than 2 billion pages, every two days. Illumina’s NovaSeq 6000 has made it possible to
produce >6 Terabases of high-quality bases per sequencing run. This huge amount keeps the cost per base low and has allowed for the development of many new applications.

With such a complete solution, what is the drawback? Usually none; but to resolve certain research questions, 150 nucleotide (nt) sequencing is not sufficient. Some cases require generating fragments up to 250 nt to uniquely map most of the reads.

PE250 reads fig.2 How to generate high quality, alignable sequence data?

Now, GenomeScan offers PE250 sequencing under ISO/IEC 17025 accreditation. Longer reads can, for example, span the highly variable regions in T-cell or B-cell receptors (TCR, BCR). Or they form ‘larger puzzle pieces’, to resolve repetitive regions. This can be beneficial for resequencing of whole genomes or microbiome sequencing.

What is the quality of those longer runs?
As is shown in the figure above, the quality stays very high during the run and produces reads that are of superior quality (high % of Q30 reads). With PE250 sequencing on the NovaSeq, GenomeScan can offer cost-effective sequencing of up to 500 nt.PE250 Tab.1 1024x161 How to generate high quality, alignable sequence data?

PE250 reads fig.3 1024x296 How to generate high quality, alignable sequence data?

Do you have questions or want to know how NGS could benefit your project? Just leave your message below and André will contact you…

 

 

GenomeScan to offer two Bioinformatics PhD traineeships as part of the EU Horizon 2020 program

By | News | No Comments

logo GenomeScan to offer two Bioinformatics PhD traineeships as part of the EU Horizon 2020 program Two EU-funded Consortium Grants for PhD training at GenomeScan

GenomeScan has been granted two Marie Skłodowska-Curie Actions within the Innovative Training Network calls of the European Union-funded Horizon 2020 Program. These PhD traineeships are part of Horizon 2020 Grants acquired by two different Consortia where Academia and Industry collaborate closely together. Recruitment of PhD candidates with a focus on Bioinformatics will start near the end of 2019 (applications are welcome as of today).

The proEVLifeCycle Project (ID 860303) aims to study the life cycle of extracellular vesicles in prostate cancer – from biogenesis and homing, to functional relevance. Prostate cancer presents as a major health care problem for men, with EU-wide approximately 365,000 new cases annually (reference https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe). Current means to identify rapid from slow progressing tumors are lacking specificity. There is an unmet need to means of non-invasive discrimination of these tumors and identification of novel targets for therapeutic intervention of high-risk tumors. The proEVLifeCycle Project will aid to the understanding of prostate cancer progression and consequently, to the implementation of novel biomarkers and therapeutic interventions to have a lasting impact on this indiscriminate and lethal disease.

The goal of the TrainCDKis Project (ID 860977) is to provide a multidisciplinary training programme to top-level young scientists to develop creative solutions for chronic kidney disease – from genetic modifiers to drug discovery. Chronic kidney disease is characterized by the progressive decline of renal function, associated with impaired quality of life and reduced life expectancy. It affects 10-15% of the worldwide population and is recognized as an increasing global health problem with a substantial burden on health-care budgets. The research projects within TrainCKDis will address key challenges focusing at genetic and epigenetic modifiers able of identifying patients that are predisposed to disease progression, biomarkers for disease monitoring and identification of novel therapeutic targets to impact the limited treatment options.

Fotos GenomeScan to offer two Bioinformatics PhD traineeships Post GenomeScan to offer two Bioinformatics PhD traineeships as part of the EU Horizon 2020 program

Erasmus MC and LUMC to co-participate in GenomeScan

By | News | 3 Comments

Erasmus MC and Leiden University Medical Center to co-participate in GenomeScan BV and extend their collaboration in the field of molecular diagnostics and R&D

 

Erasmus MC (Rotterdam, The Netherlands) announced today the acquisition of shares of the fast-growing genomics service provider GenomeScan BV based in Leiden (The Netherlands). Together with the Leiden University Medical Center (LUMC), another shareholder in GenomeScan, they are joining forces in the field of molecular diagnostics and research.

Ondertekening 190514 007 1024x683 Erasmus MC and LUMC to co participate in GenomeScanIn the fast-growing field of molecular diagnostics, it is critical to introduce and develop cutting-edge diagnostic technologies. One of these technologies is Next Generation Sequencing (NGS) that rapidly analyzes DNA and/or RNA of patients on a large scale.

GenomeScan is an ISO-accredited genomic service provider specialized in Next Generation Sequencing applications. The participation of Erasmus MC and LUMC in GenomeScan allows both UMCs to perform fast and sustainable molecular diagnostics under GenomeScan’s ISO-accreditation for NGS. Moreover, the collaboration will  increase the capacity to innovate, use new technologies and develop new applications for R&D and diagnostics in an international scientific environment.

GenomeScan’s expertise not only lies in molecular diagnostic, but also in developing customizable NGS solutions for pharmaceutical and biotech companies, academic centers and hospitals, mainly within Europe. In addition, GenomeScan collaborates with leading scientific institutes in a number of national and international research projects.

David Voetelink, vice-chairman of the Executive Board: “The Erasmus MC wants to drive innovation in healthcare and technology is becoming an increasingly important factor that requires consequent investments. Through our collaboration with the LUMC we optimize the use of capital equipment. As a result, not only we have access to the most advanced technologies, but also we have a chance to ensure that the healthcare costs remain affordable.”

Pancras Hogendoorn, vice-chairman of the Executive Board of LUMC: “The collaboration with GenomeScan and Erasmus MC fits perfectly with our strategy to develop cutting-edge applications to accelerate and improve diagnosis of patients in state-of-the art clinical research facilities. With the accession of Erasmus MC, we take a big step towards achieving this goal.”

Kees van den Berg, CEO GenomeScan: “Our partnership with both UMCs, allows GenomeScan to strengthen its engagement in developing new tools to diagnose genetic disorders quicker, affordably and more effectively. By sharing knowledge and regrouping facilities, this partnership helps the company to rapidly invest in costly emerging technologies, in a thoroughly sustainable manner, under ISO-accreditation for healthcare providers or academic research and under G(C)LP for the pharmaceutical market.”

 

About GenomeScan: As an ISO-accredited leading Dutch Next Generation Sequencing service provider, GenomeScan develops customizable NGS solutions for pharmaceutical and biotech companies, health care providers and academic institutions. By providing new tools to analyze genetic disorders quicker, affordably and effectively, GenomeScan fosters innovation through partnership with medical centers and research laboratories.

 

For more information please contact marketing@genomescan.nl